Tevogen
TVGN on Nasdaq. Market value $39m.
Should I look at this?
Look carefully before going further
Why it could be worth it
Nothing stands out yet.
What to watch out for
Read the warning sign in its own filings
This is not advice.
Who owns it
None of the long-term investors we follow own it. 31 funds in all.
Largest holders overall
- Vanguard Capital Management$135,704Cut
- Morgan Stanley$106,460Added
- AQR Capital Management$97,561New
- Goldman Sachs Group$80,163New
- Jane Street Group$63,251New
- FMR$55,615Cut
- Russell Investments Group$36,971Added
- Tower Research Capital LLC (TRC)$8,456Added
- UBS Group AG$6,130Cut
- Vanguard Fiduciary Trust$4,743Cut
From 13F filings for the quarter ended 30 June 2026.
Big holders and activists
2 investors own more than 5%.
- Saadi Ryan H.Insider or founder91.1%+16.7 ptsSince 2 November 2026
What they said
Item 4 of the Schedule 13D is hereby amended and supplemented by adding the following: The information set forth in Items 3 and 6 of this Amendment is incorporated into this Item 4 by reference.
Read the filing - Kirti DesaiInsider or founder6.3%Since 14 September 2026
What they said
Item 4 of the Schedule 13D is hereby amended and supplemented by adding the following: The information set forth in Items 3 and 6 of this Amendment is incorporated into this Item 4 by reference.
Read the filing
| Holder | Stake | Since | |
|---|---|---|---|
Saadi Ryan H. Insider or founder | 91.1%+16.7 pts | 2 November 2026 | What they saidItem 4 of the Schedule 13D is hereby amended and supplemented by adding the following: The information set forth in Items 3 and 6 of this Amendment is incorporated into this Item 4 by reference. Read the filing |
Kirti Desai Insider or founder | 6.3% | 14 September 2026 | What they saidItem 4 of the Schedule 13D is hereby amended and supplemented by adding the following: The information set forth in Items 3 and 6 of this Amendment is incorporated into this Item 4 by reference. Read the filing |
From Schedule 13D and 13G filings: anyone owning more than 5% must file one.
What insiders did
No insider bought shares on the open market in the last 12 months. 1 sold $6,635.
- Flomenberg NealSee RemarksSold
- Date
- 13 March 2026
- Shares
- 501
- Price
- $6.40
- Value
- $3,206
- Flomenberg NealSee RemarksSold
- Date
- 11 March 2026
- Shares
- 452
- Price
- $7.26
- Value
- $3,282
- Flomenberg NealSee RemarksSold
- Date
- 10 March 2026
- Shares
- 19
- Price
- $7.75
- Value
- $147
| Date | Who | Did | Shares | Price | Value |
|---|---|---|---|---|---|
| 13 March 2026 | Flomenberg Neal See Remarks | Sold | 501 | $6.40 | $3,206 |
| 11 March 2026 | Flomenberg Neal See Remarks | Sold | 452 | $7.26 | $3,282 |
| 10 March 2026 | Flomenberg Neal See Remarks | Sold | 19 | $7.75 | $147 |
From Form 4 filings: insiders must report trades in their own company's shares within two days.
Warning signs in its filings
Problems the company itself reported to the SEC, in its own words.
1 serious warning sign in Tevogen’s filings.
We look for five warning signs: doubt it can keep going, weak checks on its own accounts, a notice that its past accounts can't be relied on, a change of auditor, and one customer bringing in a big share of sales. We don't check lawsuits, investigations or debt yet.
We checked the auditor's report, internal controls, restatement notices, auditor changes and big customers in the 10-K filed 31 Mar 2026, plus the 10-Q filed 16 Nov 2026 and 8 later 8-Ks.
Weak checks on its own accounts
SeriousThe company said its checks on its own accounts did not work at the end of its latest quarter. Mistakes could slip into the numbers.
“Based upon the evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were not effective at the reasonable assurance level as of the end of the period covered by this Report due to the material weakness in our internal control over financial reporting as previously disclosed in our Annual Report.”
Show the full paragraph
Under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, we have evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period covered by this Report. Based upon the evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were not effective at the reasonable assurance level as of the end of the period covered by this Report due to the material weakness in our internal control over financial reporting as previously disclosed in our Annual Report.
From the 10-Q filed 16 November 2026, Part I, Item 4. Controls and Procedures. Read it in the filing
A 10-K is the yearly report every US company files with the SEC. An 8-K is a short notice of a big event.
The deep dive
Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.
- What the business is worth, as a range, and the margin of safety at today’s price
- Prices to start buying, buy, and buy hard
- The three things that would make this a mistake
- Every number footnoted to the filing it came from
A big holder just moved. The deep dive shows what the business is worth.
Your first deep dive is free.
Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.